Leucogen

Summary

Leucogen (CHEMBL5314921) is a phase-3 clinical-stage small molecule.

At a glance

• Status: Max clinical phase 3 (not approved)
• Modality: Small molecule
• Clinical trials: 2
• Chemistry: 295.36 Da · C14H17NO4S

Identifiers

Drug identity and classification

Field	Value
ChEMBL ID	CHEMBL5314921
Name	Leucogen
Type	Small molecule
Max phase	3
FDA approved	no
PubChem CID	101105
Molecular formula	C14H17NO4S
Molecular weight	295.36
InChIKey	XDBMTQVSHNQIFU-UHFFFAOYSA-N

SMILES: CCOC(=O)C(C1NC(CS1)C(=O)O)C2=CC=CC=C2

IUPAC name: 2-(2-ethoxy-2-oxo-1-phenylethyl)-1,3-thiazolidine-4-carboxylic acid

Also known as: Leucogen, Leukogen, NSC-400257, LEUCOGEN

Patent coverage: 44 distinct patent families (55 SureChEMBL compound mentions), from 1 matched compound structure(s). Mentions count patents naming the compound (not distinct inventions), so promiscuous / reference molecules inflate the mention figure — families are the dedup metric.

Targets

Targets

No target linkage available.

Bioactivity

No ChEMBL bioactivity rows at pChembl ≥ 5 (expected for biologics / antibodies).

Target pathways

No target-pathway data for this drug (no mapped target genes).

Indications & clinical

Indications

0 indication records carry no mapped disease name (EFO/MeSH-only); none shown.

Clinical trials

Total trials: 2.

Phase distribution

Phase	Trials
PHASE3	1
Not specified	1

Top trials by phase / activity

NCT	Phase	Status	Title
NCT05780294	PHASE3	NOT_YET_RECRUITING	A Multi-center, Randomized, Double-blind, Phase III Clinical Trial of Leucogen Versus Placebo on Leukocyte and Platelet Whole-course Management Assisted by PFLL Chemotherapy in the Treatment of Stage IV, Recurrent or Metastatic NPC
NCT07418879	Not specified	NOT_YET_RECRUITING	A Real-world Study of Pralsetinib Combined With Leucogen in the Treatment of RET Fusion-positive NSCLC

Clinical evidence (CIViC)

No CIViC predictive evidence (expected for non-precision-medicine drugs).

Pharmacology

Pharmacogenomics

No PharmGKB pharmacogenomic data curated for this drug.

Related molecules

Related molecules

No competitor molecules sharing a primary target (ChEMBL phase ≥2 or PubChem drug-class).